logo
Elio is Pixar's best, most beautifully brilliant movie in a decade. Too bad it will probably bomb

Elio is Pixar's best, most beautifully brilliant movie in a decade. Too bad it will probably bomb

CBC19-06-2025
Social Sharing
As a film, Elio is gorgeous. In short, it's a somehow equal parts miraculous and original wonder — so good it feels a bit out of place among a summer of adaptations, remakes, sequels and remakes of adaptations of sequels.
Perhaps not that last one. But it is hard to ignore the benefits of Elio: Pixar's animation style (which seemed stuck in a perpetual state of diminishing Toy Story returns) has never looked more fluidly beautiful — especially when used to create a tapestry of glittering nebulae and spaceships.
Its characters come to life with originality and heart — none more so than its heart-breakingly damaged namesake, 11-year-old Elio Solis, a space-obsessed child trying his very best to provoke an alien abduction rather than running from one.
Brushing past some of its almost too kidd-ish qualities, Elio achieves almost shocking levels of originality, beauty and terrifying tragedy that do more than earn it the title of modern classic.
That said, it's probably going to bomb.
There are more than a few reasons why that's the case for Pixar's latest release, and buckle up, because it all comes quickly.
We're introduced to the movie's heroic, pint-sized namesake with the narrative equivalent of a sledgehammer to the skull.
Elio is a silent, terrified child hiding under a restaurant table, worrying the laces of oversized shoes as he tries to spontaneously phase out of existence rather than acknowledge his aunt's futile attempts to coax him back to his chair. It's a lost cause though.
We soon learn that Elio (Yonas Kibreab) has just been orphaned, and his aunt Olga (Zoe Saldaña) is the unfortunate, too-young-for-this stopgap, burdened with unwanted parenthood she doesn't have the life skills to handle — especially while juggling her job as a major in the U.S. Air Force, overseeing an array of telescopes scanning the skies for space debris.
But Elio's no slouch. As he wanders off into the base, he's more than aware he's the one thing a child fears most — the primal, instinctive fear that eventually evolves into the scattershot assortment of neuroses we call a personality: being unwanted.
And as he stumbles into a conveniently-placed exhibit on Voyager 1 — the 1977 probe launched with a golden record, information about life on Earth and hopeful greetings for alien species — we suddenly get the animated equivalent of Citizen Kane 's Rosebud.
Lying on his back, gazing slack-jawed at a glittering star-show about humanity's search for friendly intelligence in the lonely and infinite cosmos while a single tear pools on his cheek, he understands: if no one wants him on this planet, he'll go looking for one that does want him.
But it also does more. This latest offering from Pixar has finally arrived in theatres after a year-long delay and a wildly shifting strategy, possibly resulting from its fraught behind-the-scenes trajectory.
The result is a disparate, possibly alienating tonal melange of a UFO movie — somehow even more disorganized than that congressional hearing on UFOs we are all somehow fine with having happened.
For example: Jokes, storylines and even its sometimes stilted, always hand-holdy plot beats ring of a grade-school reading level — perhaps even more childish than Pixar's increasingly tween-focused fare. But that's at cross-purposes with Canadian co-director Domee Shi's sci-fi/horror allusions that, though geared toward a younger audience, still manage to make grown-ups shiver.
How one scene depicting a disintegrating clone — almost directly lifted from Rick & Morty 's horrifying "melting clone babies" moment — will manage not to inspire a juvenile nightmare epidemic is a mystery for the ages.
Delays, rewrites
To be fair, these moments are infrequent; a scriptwriting vestigial limb of what was likely a whiplash-inducing envelope push for Pixar. Given that the once dominant-studio's last big non-sequel success was 2017's Coco, it makes sense that they'd be swinging for the fences while trying to recapture the cultural zeitgeist with Elio, at least with the initial version.
Speaking to The Wrap, Pixar chief Pete Docter claimed Elio 's delay from last year was due largely to the SAG-AFTRA strike, but behind-the-scenes changes saw the departure of much of the creative team, ushering in replacements Shee and co-director Madeline Sharafian.
That shift means the story is sometimes at odds with itself, and elsewhere obviously fractured and awkwardly reassembled.
The final version of the film has been so fundamentally altered that virtually every moment from its original trailer was purged — including one of the riskiest, genre-pushing, jokes: "I'm trying to get abducted," Elio says, before quickly clarifying: "By aliens!"
But even after the loss of some of the more risque asides, there's a seriously mature plot under the surface, one that reflects Disney's wonderfully inventive, surprisingly unsuccessful 2007 time-travel comedy Meet the Robinsons.
In that movie, there's a scene in which one character gives a singular reason for his relentless villainy.
In a flashback, we see a rage-filled, pint-sized orphan with bags under his eyes, skulking through a middle school hallway. Other children smile and wave as he passes and enthusiastically ask if he'd like to hang out after class while complimenting his "cool," flowery-pink unicorn binder.
"They all hated me," he narrates.
In Elio, our hero's Meet the Robinsons -esque trauma-borne impulse to wall himself off from love or intimacy adds the last ingredient to this frankly bizarre hodgepodge: devastating tragedy.
While it's maybe a little subtextual for the toddlers, anyone who's heard the phrase "male loneliness epidemic" will see the beginnings of mental health issues that too often morph into isolation, depression and rage. Few children's movies have grappled with this before — let alone while vesting it in such a crushingly sad character arc.
The hardest thing about watching Elio becomes keeping yourself from jumping through the screen to protect him at all costs.
And there's also another complicating plot conceit: a 1985 interview with astronomer Carl Sagan, initially about space exploration and his book Contact.
"The search for life elsewhere is remarkable in our age, because this is the first time that we can actually do something besides speculation," we hear Sagan's sage voice intone. "It touches to the deepest of human concerns: Are we alone?"
This is quickly reinterpreted through Elio 's more Earth-bound theme, as the voiceover tellingly bookends his flailings toward and away from love and acceptance, both from the aliens and Olga.
In short, it's a lot. The movie's originality is something to be marvelled at. Unfortunately, like Meet the Robinsons, it's probably too original and too divisive to find a massive audience.
A polarizing study in loneliness that, unlike the , is anything but conventional, Elio
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment
Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment

Globe and Mail

time7 hours ago

  • Globe and Mail

Mycosis Fungoides Pipeline Appears Robust With 4+ Key Pharma Companies Actively Working in the Therapeutics Segment

DelveInsight's, ' Mycosis Fungoides Pipeline Insight, 2025 ' report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Mycosis Fungoides pipeline landscape. It covers the Mycosis Fungoides pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mycosis Fungoides pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Mycosis Fungoides Pipeline. Dive into DelveInsight's comprehensive report today! @ Mycosis Fungoides Pipeline Outlook Key Takeaways from the Mycosis Fungoides Pipeline Report In June 2025, M.D. Anderson Cancer Center announced a study of ultra-low-dose-total-skin electron beam therapy with brentuximab vedotin (ULD-TSEBT+BV) among patients with stage I-IV mycosis fungoides/Sezary syndrome. In June 2025, Soligenix conducted a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. All of the participant's lesions that are readily available for exposure to the visible light source will be treated and 3 to 5 index lesions in each patient will be prospectively identified and documented for modified Composite Assessment of Index Lesion Severity (mCAILS) evaluation. Participants will be followed every 4 weeks for a total of 12 weeks following their last light session. DelveInsight's Mycosis Fungoides Pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for Mycosis Fungoides treatment. The leading Mycosis Fungoides Companies such as Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Promising Mycosis Fungoides Pipeline Therapies such as Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Stay ahead with the most recent pipeline outlook for Mycosis Fungoides. Get insights into clinical trials, emerging therapies, and leading companies with Mycosis Fungoides @ Mycosis Fungoides Treatment Drugs Mycosis Fungoides Emerging Drugs Profile Hypericin: Soligenix HyBryte™ (research name SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by safe, visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. Currently, the drug is in Phase III stage of its development for the treatment of Mycosis Fungoides. IPH4102: Innate Pharma Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and peripheral T cell lymphoma (PTCL). Lacutamab has been granted U.S. FDA Breakthrough Therapy Designation for relapsed or refractory Sézary syndrome. Innate Pharma SA announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sézary syndrome (SS) after at least 2 prior systemic therapies including mogamulizumab. Currently, the drug is in Phase II stage of its development for the treatment of Mycosis Fungoides. The Mycosis Fungoides Pipeline Report Provides Insights into- The report provides detailed insights about companies that are developing therapies for the treatment of Mycosis Fungoides with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mycosis Fungoides Treatment. Mycosis Fungoides Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Mycosis Fungoides Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mycosis Fungoides market Explore groundbreaking therapies and clinical trials in the Mycosis Fungoides Pipeline. Access DelveInsight's detailed report now! @ New Mycosis Fungoides Drugs Mycosis Fungoides Companies Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Mycosis Fungoides Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Mycosis Fungoides Treatment. Learn about new drugs, Mycosis Fungoides Pipeline developments, and key companies with DelveInsight's expert analysis @ Mycosis Fungoides Market Drivers and Barriers Scope of the Mycosis Fungoides Pipeline Report Coverage- Global Mycosis Fungoides Companies- Innate Pharma, Soligenix, Bristol-Myers Squibb and others. Mycosis Fungoides Pipeline Therapies- Brentuximab vedotin, mechlorethamine-MCH (nitrogen mustard), Hypericin, Ritlecitinib, Methoxsalen+ECP, AFM13 and others. Mycosis Fungoides Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Mycosis Fungoides Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Mycosis Fungoides Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Mycosis Fungoides Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Mycosis Fungoides: Overview Pipeline Therapeutics Therapeutic Assessment Mycosis Fungoides– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Hypericin: Soligenix Drug profiles in the detailed report….. Mid Stage Products (Phase II) IPH4102: Innate Pharma Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug Name: Company Name Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Mycosis Fungoides Key Companies Mycosis Fungoides Key Products Mycosis Fungoides- Unmet Needs Mycosis Fungoides- Market Drivers and Barriers Mycosis Fungoides- Future Perspectives and Conclusion Mycosis Fungoides Analyst Views Mycosis Fungoides Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

'He's still collecting the cheque': Will the Diddy verdict have any consequences on the mogul?
'He's still collecting the cheque': Will the Diddy verdict have any consequences on the mogul?

CBC

time8 hours ago

  • CBC

'He's still collecting the cheque': Will the Diddy verdict have any consequences on the mogul?

Social Sharing WARNING: This story contains allegations of ​​​sexual violence and may affect those who have experienced​ it or know someone impacted by it. The split verdict for the trial of Sean "Diddy" Combs came in yesterday. The jury found the hip-hop mogul guilty of two charges of transportation to engage in prostitution, and not guilty of three charges of sex trafficking and racketeering, which could have put him behind bars for life. But the online chatter around Diddy and his legacy have become just as big a conversation as the trial. Today on Commotion, guest host Rad Simonpillai is joined by Refinery29 Diddy trial reporter Taryn Finley and hip-hop broadcaster Jay Smooth to react to the news, the discourse around the case and what it all might mean for Diddy's pop legacy moving forward. We've included some highlights below, edited for length and clarity. For the full discussion, listen and follow Commotion with Elamin Abdelmahmoud on your favourite podcast player. WATCH | Today's episode on YouTube: Rad: Can you talk to me about the online discourse and what stood out to you about how people have been discussing this trial? Taryn: A lot of it has just been plain ugly. I want some of these folks to just say that they hate women with their chest and move on because that's really what they mean when they're using this victim-blaming language with Cassie [Ventura, Diddy's ex-girlfriend] and these other accusers saying, "Oh, they just want money" and "Oh, it wasn't a problem when XYZ." That, again, shows how deeply flawed and deeply ignorant a lot of people are to the pain and suffering that these victims have gone through. When you listen to what they're saying, even on a human level, it doesn't add up to me how a lot of comments can be so cruel and how folks can be outside of the courthouse post verdict, dousing themselves and each other in baby oil. Unfortunately, again, it's not surprising. We've seen this kind of rallying around Tory Lanez and R. Kelly and Bill Cosby and so many others. And the lack of empathy that is being extended for these victims is not only dark and dehumanizing, but we've become so desensitized to sexual assault and violence allegations in the worst way. And we have to do better. Jay: Yeah, it really was such a grotesque spectacle. And what was interesting to me is the vibe of some of those videos outside the courtroom. They reminded me of some of the clips we saw on Jan. 6 outside the Capitol, this similar sort of lunatic energy. And I don't think that's a coincidence. Because just like our politics are being poisoned by this whole right-wing, manosphere media ecosystem, on the cultural side, those people outside the courtroom are forming their worldview from a steady diet of these garbage drama channels and influencers whose whole business model is to peddle misinformation on a case like this that taps into your worst instincts and prejudices, just like we watched people make millions of dollars from demonizing Megan Thee Stallion for three years. Those people outside of the courtroom have had an appetite for this salacious dehumanization of these women, and of course we see them go out there and treat the whole situation like a farce. So I think it's a really telling sign of the times, in a lot of ways, for how unserious we are and how much of an appetite we have for hating women, like Taryn said. Rad: That is so depressing to hear all of that. I want to get into another aspect of it — setting aside the trial and everything — but just thinking about Diddy as someone who's had this undeniable impact on pop music, pop culture as we know it. How do you think the split verdict then impacts his legacy moving forward? Taryn: I think a lot of his fans and a lot of folks will also be split. It will be a split decision culturally, where some folks will continue to dance to his music and Diddy bop and do all of that, while others will boo the DJ and tell him to turn it off. But bigger than music, though, we also have to consider this is a businessman and he has been a businessman for decades. And even though he's sullied his name and sits in prison now, he's still collecting the cheque. And that won't end. He'll no longer be able to be the face of brands like DeLeón [tequila] and Revolt [media company] and be the head of these big media companies, but Diddy is savvy and well-connected. And many won't want to touch him publicly, not necessarily just because of the moral aspect, but because they're afraid of their reputation being hurt, which is a whole other conversation in itself. But there always will be someone who will. Jay: My personal feeling is I don't care what happens to Diddy's legacy. This is not like a Dr. Dre situation, where you have a genuinely great artist who made big contributions creatively and he also has an ugly history of abuse. That's not who Diddy is. Diddy, I guess, he ushered in the shiny suit era of vapid materialism into music — which is like, thanks a lot. Other than that, he's a megalomaniacal businessman who's really good at self-promotion and finagled his way into a lot of production credits he only halfway deserves. So as far as I'm concerned, throw that legacy away. Use AI to take him off the Biggie tracks and we can move on. The reality is, of course, he's going to be fine, for all the reasons Taryn said. And really, when I think about legacy, I look at all these women who stepped up to tell their story and I want to know: will they get to have a legacy? And that's going to be up to us with what we do to take what they did and make it count. At the risk of being cheesy, I think that's what I'm more concerned with in terms of legacy.

What is the essence of cool? A global study narrows it down to 6 key traits
What is the essence of cool? A global study narrows it down to 6 key traits

CBC

time9 hours ago

  • CBC

What is the essence of cool? A global study narrows it down to 6 key traits

Cool is cool, no matter where you are in the world. That's the conclusion of a new study that surveyed nearly 6,000 people in 13 different countries about what makes a person cool, and found the answers to be surprisingly universal. "We wanted to [look at] the deeper characteristics associated with cool people. How do those change across cultures?" Caleb Warren, an associate professor of marketing at the University of Arizona, told As It Happens host Nil Köksal. "We found that, largely, they don't." The study, published in the Journal of Experimental Psychology identifies six perceived traits associated with cool people: extroverted, hedonistic, powerful, adventurous, open and autonomous. And "perceived" is the key word here. "Cool is an impression we have of others," Warren said. "And I think, like other impressions, we form these almost instantaneously." The difference between 'cool' and 'good' The researchers surveyed 5,943 people online between 2018 and 2022 in the United States, Australia, Chile, China, Germany, India, Mexico, Nigeria, Spain, South Africa, South Korea and Turkey. They asked each participant to think of four specific people: someone cool, someone not cool, someone good, and someone not good. They then had the participants fill out questionnaires evaluating the personality traits of those people. "The question we wanted to ask in this research is: Is cool the same or just another way of saying you like someone, or you think they're good?" Warren said. "And so what we tried to do is distinguish cool people from good people." They found there is, indeed, some overlap between the two — but also some very big differences. Broadly, the authors say, good people were described as more agreeable, conforming, traditional, secure, warm, conscientious and calm. "Its not that being bad will make somebody cool," Warren said. "I think being different or distinct or counter-normative is … what ends up making people cool." 'One of the most important American cultural exports' Rebellion is and always has been at the very heart of cool, says author and professor Joel Dinerstein. "Contemporary cool owes everything to rebel counter-cultural movements, from Black jazz musicians to the [Beat Generation] to the punks," he told CBC in an email. Dinerstein has been teaching a class called "The History of Cool" for almost 20 years at Tulane University in New Orleans. He's also the author of The Origins of Cool and curated the National Portrait Gallery exhibit American Cool. He traces the origins of cool to the post-Second World War jazz scene, when Black musicians began "defying racism through language, style, and a nonchalant (cool) demeanour." In fact, he says, it was U.S. jazz saxophonist Lester Young who coined the modern usage of the word. Despite cool's distinctly American origins, Dinerstein wasn't at all surprised by the study's conclusion that cool is a universal concept. "Cool has been a global concept for more than a half-century," he said. "It is one of the most important American cultural exports, along with the nation's music and sports." Even the word "cool" has become universal across different languages, Warren said. "In our survey, we asked people about the word cool without trying to translate it," he said. "And so both the word and meaning have spread around the world, with the meaning largely intact." Is capitalism ruining cool? But as coolness spreads, does it lose its edge? The study's authors say that over the years, coolness has strayed from its counterculture origins and morphed into something "more mainstream" and "commercially friendly," with major brands like Pepsi and Nike turning it into a commodity. But Dinerstein isn't too worried. "I don't think corporate interests ever truly define cool as much as they, or the media, or certain lazy writers think," he said. Francis McAndrew — a social psychologist at Knox College and Illinois who has written about the concept of coolness —agrees. "I don't think that pop culture and advertising are creating the image of what it means to be cool as much as they are relentlessly reminding us about it to sell us stuff," he said. Ultimately, Warren says the value of coolness lies in its power to alter the status quo by raising the social status of people who "are able to move a culture forward by innovating or coming up with new ideas." It's also, he says, not easily manufactured. In a separate research project he's working on, he's found that people who actively try be cool are usually perceived as less cool.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store